ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1981

High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education

Kami Roake1, Natalie Morlan1, Stephanie Lim1, Jennifer Giles1, Anthony Minjarez2, Grant Cannon3, Nadia Grant4, Vivianne Allsop5, Miranda Jensen1, Madeline O'Sullivan1, Christopher Ching1, Michael Bessen1, Javier Rios6 and Jessica A. Walsh7, 1University of Utah, Salt Lake City, UT, 2Salt Lake City VA, Salt Lake City, UT, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4University of Utah, Salt Lake City, 5University of Utah, South Jordan, UT, 6University of Utah Health, Salt Lake City, UT, 7Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT

Meeting: ACR Convergence 2025

Keywords: Access to care, education, patient, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1972–1989) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patient education is critical for managing rheumatic diseases. Rheumatology clinic pharmacists are well-positioned to assess and address gaps in patients’ understanding of their medications. The objective of this study was to determine patient satisfaction and assess patient understanding of rheumatology medications after a pharmacist-led education (PURPLE) in patients starting new treatment for a rheumatic disease.

Methods: Patients attending a rheumatology clinic at the University of Utah (UoU) or Salt Lake City Veterans Affairs Health (VA) who were initiating or switching a disease-modifying antirheumatic drug (i.e., conventional synthetic-, biologic-, and targeted synthetic- DMARDs) received initial medication education by the rheumatologist and/or the clinic pharmacist, per standard-of-care practice. Patients were offered a virtual or phone appointment with a rheumatology clinical pharmacist, approximately 2-4 weeks later. The appointments included 1) a structured assessment of the patients’ knowledge about their medication and 2) education tailored to each patients’ education needs and questions. After the appointment, patients were invited to complete an anonymous survey assessing their satisfaction and knowledge learned during the education appointment.

Results: Among the 62 participants who completed the survey, 49 were from the UoU and 13 from the VA. Patients agreed or strongly agreed the PURPLE education visit was worthwhile (94%), increased their comfort with medication safety (92%), improved their confidence in the medication effectiveness (89%), and provided useful information (95%) (Figure 1). Satisfaction rates were similar between the patient subsets from the UoU and VA (Figure 2). The most frequent categories of information learned during the visit included potential medication related adverse events, what to do if an adverse event occurs, how to administer the medication, and anticipated time to maximum effectiveness (time to onset) (Figure 3).

Conclusion: Patients reported high satisfaction with the PURPLE program. The similarity in outcomes between the clinic sites suggests the program is applicable across different health care systems. These findings underscore the value of personalized, pharmacist-led education for patients receiving treatment for rheumatic diseases.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Roake: American Pharmacist Association (APhA), 6; N. Morlan: None; S. Lim: None; J. Giles: None; A. Minjarez: None; G. Cannon: None; N. Grant: None; V. Allsop: None; M. Jensen: None; M. O'Sullivan: None; C. Ching: None; M. Bessen: None; J. Rios: None; J. Walsh: AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Merck, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Spyre, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Roake K, Morlan N, Lim S, Giles J, Minjarez A, Cannon G, Grant N, Allsop V, Jensen M, O'Sullivan M, Ching C, Bessen M, Rios J, Walsh J. High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/high-patient-satisfaction-with-a-medication-education-program-program-to-understand-rheumatology-medications-with-pharmacist-led-education/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-patient-satisfaction-with-a-medication-education-program-program-to-understand-rheumatology-medications-with-pharmacist-led-education/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology